Literature DB >> 10692435

DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).

S Milutinovic1, J D Knox, M Szyf.   

Abstract

Previous lines of evidence have shown that inhibition of DNA methyltransferase (MeTase) can arrest tumor cell growth; however, the mechanisms involved were not clear. In this manuscript we show that out of 16 known tumor suppressors and cell cycle regulators, the cyclin-dependent kinase inhibitor p21 is the only tumor suppressor induced in the human lung cancer cell line, A549, following inhibition of DNA MeTase by a novel DNA MeTase antagonist or antisense oligonucleotides. The rapid induction of p21 expression points to a mechanism that does not involve demethylation of p21 promoter. Consistent with this hypothesis, we show that part of the CpG island upstream of the endogenous p21 gene is unmethylated and that the expression of unmethylated p21 promoter luciferase reporter constructs is induced following inhibition of DNA MeTase. These results are consistent with the hypothesis that the level of DNA MeTase in a cell can control the expression of a nodal tumor suppressor by a mechanism that does not involve DNA methylation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692435     DOI: 10.1074/jbc.275.9.6353

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.

Authors:  Yutaka Kondo; LanLan Shen; Jean-Pierre J Issa
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 2.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities.

Authors:  Lirong Peng; Zhigang Yuan; Hongbo Ling; Kenji Fukasawa; Keith Robertson; Nancy Olashaw; John Koomen; Jiandong Chen; William S Lane; Edward Seto
Journal:  Mol Cell Biol       Date:  2011-09-26       Impact factor: 4.272

4.  Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.

Authors:  Jaideep V Thottassery; Vijaya Sambandam; Paula W Allan; Joseph A Maddry; Yulia Y Maxuitenko; Kamal Tiwari; Melinda Hollingshead; William B Parker
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-08       Impact factor: 3.333

5.  AUF1 cell cycle variations define genomic DNA methylation by regulation of DNMT1 mRNA stability.

Authors:  Jerome Torrisani; Alexander Unterberger; Sachin R Tendulkar; Keisuke Shikimi; Moshe Szyf
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 6.  Genes, chromatin, and breast cancer: an epigenetic tale.

Authors:  L M Mielnicki; H L Asch; B B Asch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

Review 7.  Effects of histone acetylation and DNA methylation on p21( WAF1) regulation.

Authors:  Jing-Yuan Fang; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

8.  HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).

Authors:  Mingtao Liu; Jennie Wang; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2016-09-09       Impact factor: 3.935

9.  Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.

Authors:  Wei-Guo Zhu; Kanur Srinivasan; Zunyan Dai; Wenrui Duan; Lawrence J Druhan; Haiming Ding; Lisa Yee; Miguel A Villalona-Calero; Christoph Plass; Gregory A Otterson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.

Authors:  William R Burns; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.